Triptorelin Market in Depth Research and Forecast by 2027 : CMI Research
Triptorelin can also be effective in the treatment of Central Precocious Puberty (CPP) in children two years of age or above. Increasing approval and launch of novel products is expected to boost growth of the market. For instance, in July 2017, the U.S. Food and Drug Administration (FDA) approved Arbor Pharmaceuticals': Triptodur for the treatment of central precocious puberty in pediatric patients. The approval was given on the grounds of a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK]...
View full press release